Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2026)
Scilex Holding (SCLXW) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
169.93% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-52.86% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-45.83% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-185.57% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
4.37% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
54.81% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-9.62% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
9.17% |
| 10 |
Scilex Holding |
- |
- |
4.15 Mn |
-177.88% |
| Date | Value |
|---|
| Mar 31, 2026 |
-177.88% |
| Dec 31, 2025 |
-197.46% |
| Sep 30, 2025 |
-3,722.41% |
| Jun 30, 2025 |
3.26% |
| Mar 31, 2025 |
72.87% |
| Dec 31, 2024 |
1,988.00% |
| Sep 30, 2024 |
7.94% |
| Jun 30, 2024 |
-3,936.84% |
| Mar 31, 2024 |
-3,686.36% |
| Dec 31, 2023 |
-92.31% |
| Sep 30, 2023 |
-493.75% |
| Jun 30, 2023 |
-46.15% |
| Mar 31, 2023 |
-214.29% |
| Dec 31, 2022 |
80.00% |
| Sep 30, 2022 |
300.00% |
| Jun 30, 2022 |
-1,200.00% |
| Mar 31, 2022 |
-117.95% |
| Dec 31, 2021 |
-1,276.34% |
| Jun 30, 2021 |
100.00% |
| Mar 31, 2021 |
100.01% |
